At Mays Cancer Center at 天美传媒, we are revolutionizing cancer care through breakthrough research, cutting-edge treatments and a deep commitment to saving lives. Our work doesn鈥檛 stop in the lab鈥攚e bring discoveries to the patient鈥檚 bedside, ensuring the latest advancements in cancer care are accessible to those who need them most. With a multidisciplinary team of experts, we provide best-in-class therapies, giving patients and their families hope, healing and life-changing support every step of the way.
As the only National Cancer Institute (NCI)-designated Cancer Center in South Texas, the Mays Cancer Center serves a vast 38-county region with over 5 million residents. Our team of more than 300 cancer researchers and clinicians is dedicated to transforming the way cancer is diagnosed, treated and prevented鈥攏ot just in San Antonio and South Texas, but worldwide.
Our 175+ active clinical trials offer patients groundbreaking new treatment options.
Pioneering Pediatric Cancer Research
The Greehey Children鈥檚 Cancer Research Institute at 天美传媒 is one of only two institutes in the U.S. exclusively dedicated to pediatric cancer research. Home to more than a dozen laboratories, the institute is at the forefront of cancer genomics, DNA repair, RNA biology and drug development鈥攁ll with the goal of creating safer, more effective and less toxic treatments for childhood cancers.
At 天美传媒, we are more than a cancer center鈥攚e are a beacon of hope, a hub of innovation and a leader in the fight against cancer.
Join us in the fight. Together, we are making a difference!
Only National Cancer Institute-designated cancer center in South Texas
300+ cancer researchers and clinicians
World-renowned Breast Cancer Symposium
In The News
天美传媒鈥檚 advanced endoscopy team leads efforts in early detection and prevention Gastrointestinal cancers were previously believed to primarily affect older adults, but over the past two decades, rates of these cancers have increased dramatically in people under age 50. A new report from the Dana-Farber Cancer Institute reveals that colorectal, pancreatic, esophageal [鈥
More than 70% of all cancers are impacted by mutations caused by a group of DNA-editing enzymes that drives tumor growth and drug resistance. The apolipoprotein B mRNA-editing enzyme catalytic polypeptide, or APOBEC, family, is a dominant factor in many cancers including bladder, breast, cervical, head and neck and lung. The University of Texas [鈥
When a protein is modified inside the cell, it can change how that protein works, either by turning on or shutting off vital functions. One important system that controls these changes is called the small ubiquitin-like modifier, or SUMO, pathway, which affects many actions including DNA repair and stress response. Scientists at The University [鈥